Baseline characteristics for patients with a diagnosis of low-grade (Gleason score 6) prostate cancer
| Characteristic | Management approach; no. (%) of patients* | p value | |
|---|---|---|---|
| Active surveillance n = 210 | Immediate treatment n = 244 | ||
| Age, yr, mean ± SD | 65.2 ± 7.0 | 60.9 ± 7.1 | < 0.001 |
| Charlson comorbidity index | |||
| 0 | 148 (70.5) | 193 (79.1) | 0.03 |
| 1 | 39 (18.6) | 39 (16.0) | |
| ≥ 2 | 23 (11.0) | 12 (4.9) | |
| Family history of prostate cancer | |||
| Yes | 39 (18.6) | 63 (25.8) | 0.1 |
| No | 143 (68.1) | 159 (65.2) | |
| Unknown | 28 (13.3) | 22 (9.0) | |
| PSA at biopsy, ng/mL, mean ± SD | 6.9 ± 6.1 | 6.4 ± 4.4 | 0.4 |
| Clinical tumour (cT) stage | |||
| cT1 (not palpable) | 185 (88.1) | 196 (80.3) | 0.02 |
| ≥ cT2 (palpable) | 25 (11.9) | 48 (19.7) | |
| PSA density, ng/mL2 | n = 243 | ||
| ≤ 0.2 | 157 (74.8) | 153 (63.0) | 0.007 |
| > 0.2 | 53 (25.2) | 90 (37.0) | |
| No. of positive biopsy cores | n = 244 | ||
| ≤ 2 | 172 (81.9) | 121 (49.6) | < 0.001 |
| > 2 | 38 (18.1) | 123 (50.4) | |
| Highest % cancer in a biopsy core | |||
| ≤ 50 | 195 (92.9) | 200 (82.0) | < 0.001 |
| > 50 | 15 (7.1) | 44 (18.0) | |
Note: PSA = prostate-specific antigen, SD = standard deviation.
↵* Except where indicated otherwise.